Picture of Qurient Co logo

115180 Qurient Co Share Price

0.000.00%
kr flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-0.19%
3m+4.65%
6m+17.85%
1yr-29.03%
Volume Change (%)
10d/3m-74.06%
Price vs... (%)
52w High-46.79%
50d MA+5.23%
200d MA+3.03%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-46.26%
Return on Equity-55.32%
Operating Margin-257.02%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Qurient Co EPS forecast chart

Profile Summary

Qurient Co., Ltd. is a Korea-based company mainly engaged in the research and development of pharmaceuticals. The Company includes two programs: development phase programs and research phase programs. The development phase programs consist of Q203 which is drug-resistant tuberculosis treatment drug, Q301 which is atopic dermatitis treatment dug and Q701 which is used for treatment of drug resistant cancer and promotion anti-cancer immunotherapy. The research phase programs consist of 5 lipoxygenase (5LO) inhibit asthma medicines and cyclin dependent kinase 7 (CDK7) inhibit cancer drug.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
July 2nd, 2008
Public Since
February 29th, 2016
No. of Shareholders
16,316
No. of Employees
22
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
kr flag iconKorea Exchange - KOSDAQ
Shares in Issue
27,250,001

115180 Share Price Performance

Upcoming Events for 115180

Q1 2024 Qurient Co Ltd Earnings Release

Q2 2024 Qurient Co Ltd Earnings Release

Similar to 115180

Picture of AbClon logo

AbClon

kr flag iconKorea Exchange - KOSDAQ

Picture of ADBiotech Co logo

ADBiotech Co

kr flag iconKorea Exchange - KOSDAQ

Picture of Ahn-Gook Pharmaceutical Co logo

Ahn-Gook Pharmaceutical Co

kr flag iconKorea Exchange - KOSDAQ

Picture of Alteogen logo

Alteogen

kr flag iconKorea Exchange - KOSDAQ

Picture of Aminologics Co logo

Aminologics Co

kr flag iconKorea Exchange - KOSDAQ

FAQ